Telemonitoring blood pressure in patients with chronic kidney disease
Official title: Telemonitoring and Case Management for Hypertensive and Remote-dwelling Patients With Chronic Kidney Disease - The Telemonitoring for Improved Kidney Outcomes Study (TIKO): A Clinical Research Protocol
Run by University of Alberta · NCT04098354 · Data updated 2026-11-12
This study is testing if using home blood pressure monitoring along with extra support can help people with high blood pressure and chronic kidney disease manage their condition better than standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 146 (estimated) |
| Sponsor | University of Alberta Academic / other |
| Locations | 1 site (Edmonton, Albert) |
| Status | Recruiting |
| Started | April 15, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT04098354 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with chronic kidney disease, hypertension, and access to a smartphone and internet.
✕Probably not a fit
Patients with severe chronic kidney disease (stage 5) or those experiencing hypertensive emergencies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of home blood pressure telemonitoring (HBPT) combined with clinical case management compared to HBPT with usual care in patients with hypertension and chronic kidney disease (CKD) living in Northern Alberta. The primary focus is to assess the mean difference in systolic blood pressure over 12 months. Additionally, the study will explore the cost-effectiveness and acceptability of HBPT, as well as monitor any adverse events. The study is designed as a pragmatic randomized controlled trial to provide insights into managing hypertension in remote populations.
Why it matters
Potential benefit: If successful, this approach could lead to better blood pressure control and improved health outcomes for patients with chronic kidney disease.
How similar studies have gone: Previous studies have shown positive outcomes with home blood pressure telemonitoring in similar populations, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age equal to and more than 18 years with documented diagnosis of established CKD (not on dialysis with eGFR \< 60 mL/min/1.73m2 and/or proteinuria \> 1 g/day) * Remote dwelling patients in the Peace River region of Alberta, Canada * Patients known with hypertension (physician diagnosed / self reported and currently taking antihypertensive medications) * Owning a smartphone (iOS or Android) with access to wireless internet connection. * Proficiency in English language (both verbal and written); and ability and willingness to provide informed consent for participation. * Ability and willingness to use the HBPT device (≥ 80% recordings sent in the training period) Exclusion Criteria: * Patients with hypertensive urgency or emergency identified during the training period (immediate consultation will be initiated with the patient's PCP or with a hypertension specialist) * Patients with stage 5 CKD (eGFR ≤ 15 ml/min/1.73m2) or patients receiving kidney replacement therapy * Heart failure with reduced ejection fraction * Presence of any terminal illness (life expectancy \< 1 year) * Participation in any ongoing clinical drug trial * Pregnancy, lactation / breastfeeding * Planning to relocate out of the Peace River region or residence in an area without mobile phone coverage.
Where it's running
-
University of Alberta
Edmonton, Albert, Canada Recruiting
Study contacts
- Principal investigator: Aminu Bello — University of Alberta
- Study coordinator: Deenaz Zaidi
- Email: deenaz@ualberta.ca
- Phone: 17807098964
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Impact of TAVR on kidney function in people with aortic valve disease
This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.
-
Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs
This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
-
Eye-brain-kidney connections in chronic kidney disease
This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.
-
Screening for chronic kidney disease
We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.